Are gonadotrophins tumorigenic-A critical review of clinical and experimental data

Molecular and Cellular Endocrinology

Volumn 329, Issue 1-2, 2010, Pages 56-61

  Huhtaniemi, Ilpo ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Adrenal tumors; Breast cancer; Gonadotrophin receptors; Ovarian cancer; Prolactinoma; Prostatic cancer

Indexed keywords

CHORIONIC GONADOTROPIN RECEPTOR; GONADOTROPIN; GONADOTROPIN RECEPTOR; LUTEINIZING HORMONE; LUTEINIZING HORMONE RECEPTOR; MESSENGER RNA;

BREAST CANCER; CARCINOGENESIS; GENE EXPRESSION REGULATION; GENE INDUCTION; HUMAN; IN SITU HYBRIDIZATION; LEYDIG CELL; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SERTOLI CELL; SIGNAL TRANSDUCTION; TESTIS CANCER; THECA CELL; TUMOR GROWTH; UPREGULATION;

FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPINS; HUMANS; LUTEINIZING HORMONE; MALE; NEOPLASMS;

EID: 77957132947     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.04.028     Document Type: Review

References (79)

1. Ahtiainen P., Rulli S.B., Shariatmadari R., Pelliniemi L.J., Toppari J., Poutanen M., Huhtaniemi I.T. Fetal but not adult Leydig cells are susceptible to adenoma formation in response to persistently high hCG level: a study on hCG overexpressing transgenic mice. Oncogene 2005, 24:7301-7309.
2. Akhmedkhanov A., Toniolo P., Zeleniuch-Jacquotte A., Pettersson K.S., Huhtaniemi I.T. Luteinizing hormone, its beta-subunit variant, and epithelial ovarian cancer: the gonadotropin hypothesis revisited. Am. J. Epidemiol. 2001, 154:43-49.
3. Ameryckx L., Fatemi H.M., De Sutter P., Amy J.J. GnRH antagonist in the adjuvant treatment of a recurrent ovarian granulosa cell tumor: a case report. Gynecol. Oncol. 2005, 99:764-766.
4. Arslan A.A., Zeleniuch-Jacquotte A., Lundin E., Micheli A., Lukanova A., Afanasyeva Y., Lenner P., Krogh V., Muti P., Rinaldi S., Kaaks R., Berrino F., Hallmans G., Toniolo P. Serum follicle-stimulating hormone and risk of epithelial ovarian cancer in postmenopausal women. Cancer Epidemiol. Biomark. Prev. 2003, 12:1531-1535.
5. Balbi G., Piano L.D., Cardone A., Cirelli G. Second-line therapy of advanced ovarian cancer with GnRH analogs. Int. J. Gynecol. Cancer 2004, 14:799-803.
6. Ben-Josef E., Yang S.Y., Ji T.H., Bidart J.M., Garde S.V., Chopra D.P., Porter A.T., Tang D.G. Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J. Urol. 1999, 161:970-976.
7. Bernichtein S., Alevizaki M., Huhtaniemi I. Is the adrenal cortex a target for gonadotropins?. Trends Endocrinol. Metab. 2008, 19:231-238.
8. Bertherat J., Contesse V., Louiset E., Barrande G., Duparc C., Groussin L., Emy P., Bertagna X., Kuhn J.M., Vaudry H., Lefebvre H. In vivo and in vitro screening for illegitimate receptors in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome: identification of two cases of gonadotropin/gastric inhibitory polypeptide-dependent hypercortisolism. J. Clin. Endocrinol. Metab. 2005, 90:1302-1310.
9. Biskind M.S., Biskind G.S. Development of tumors in the rat ovary after transplantation into the spleen. Proc. Soc. Exp. Biol. Med. 1944, 55:176-179.
10. Bodek G., Rahman N.A., Zaleska M., Soliymani R., Lankinen H., Hansel W., Huhtaniemi I., Ziecik A.J. A novel approach of targeted ablation of mammary carcinoma cells through luteinizing hormone receptors using Hecate-CGbeta conjugate. Breast Cancer Res. Treat. 2003, 79:1-10.
11. Bodek G., Vierre S., Rivero-Muller A., Huhtaniemi I., Ziecik A.J., Rahman N.A. A novel targeted therapy of Leydig and granulosa cell tumors through the luteinizing hormone receptor using a hecate-chorionic gonadotropin beta conjugate in transgenic mice. Neoplasia 2005, 7:497-508.
12. Bose C.K. Follicle stimulating hormone receptor in ovarian surface epithelium and epithelial ovarian cancer. Oncol. Res. 2008, 17:231-238.
13. Burdette J.E., Kurley S.J., Kilen S.M., Mayo K.E., Woodruff T.K. Gonadotropin-induced superovulation drives ovarian surface epithelia proliferation in CD1 mice. Endocrinology 2006, 147:2338-2345.
14. Choi J.H., Choi K.C., Auersperg N., Leung P.C. Gonadotropins upregulate the epidermal growth factor receptor through activation of mitogen-activated protein kinases and phosphatidyl-inositol-3-kinase in human ovarian surface epithelial cells. Endocr. Relat. Cancer 2005, 12:407-421.
15. Choi J.H., Wong A.S., Huang H.F., Leung P.C. Gonadotropins and ovarian cancer. Endocr. Rev. 2007, 28:440-461.
16. Davies B.R., Finnigan D.S., Smith S.K., Ponder B.A. Administration of gonadotropins stimulates proliferation of normal mouse ovarian surface epithelium. Gynecol. Endocrinol. 1999, 13:75-81.
17. Dirnhofer S., Berger C., Hermann M., Steiner G., Madersbacher S., Berger P. Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate. Prostate 1998, 35:212-220.
18. Emons G., Ortmann O., Teichert H.M., Fassl H., Lohrs U., Kullander S., Kauppila A., Ayalon D., Schally A., Oberheuser F. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group. Cancer 1996, 78:1452-1460.
19. Feelders R.A., Lamberts S.W., Hofland L.J., van Koetsveld P.M., Verhoef-Post M., Themmen A.P., de Jong F.H., Bonjer H.J., Clark A.J., van der Lely A.J., de Herder W.W. Luteinizing hormone (LH)-responsive Cushing's syndrome: the demonstration of LH receptor messenger ribonucleic acid in hyperplastic adrenal cells, which respond to chorionic gonadotropin and serotonin agonists in vitro. J. Clin. Endocrinol. Metab. 2003, 88:230-237.
20. Filicori M., Fazleabas A.T., Huhtaniemi I., Licht P., Rao Ch V., Tesarik J., Zygmunt M. Novel concepts of human chorionic gonadotropin: reproductive system interactions and potential in the management of infertility. Fertil. Steril. 2005, 84:275-284.
21. Fishman A., Kudelka A.P., Tresukosol D., Edwards C.L., Freedman R.S., Kaplan A.L., Girtanner R.E., Kavanagh J.J. Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. J. Reprod. Med. 1996, 41:393-396.
22. Gebauer G., Mueller N., Fehm T., Berkholz A., Beck E.P., Jaeger W., Licht P. Expression and regulation of luteinizing hormone/human chorionic gonadotropin receptors in ovarian cancer and its correlation to human chorionic gonadotropin-doxorubicin sensitivity. Am. J. Obstet. Gynecol. 2004, 190:1621-1628. (discussion 1628).
23. Gubbay O., Rae M.T., McNeilly A.S., Donadeu F.X., Zeleznik A.J., Hillier S.G. cAMP response element-binding (CREB) signalling and ovarian surface epithelial cell survival. J. Endocrinol. 2006, 191:275-285.
24. Hamalainen T., Poutanen M., Huhtaniemi I. Promoter function of different lengths of the murine luteinizing hormone receptor gene 5'-flanking region in transfected gonadal cells and in transgenic mice. Endocrinology 2001, 142:2427-2434.
25. Hasan J., Ton N., Mullamitha S., Clamp A., McNeilly A., Marshall E., Jayson G.C. Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. Br. J. Cancer 2005, 93:647-651.
26. Ho S.M., Lau K.M., Mok S.C., Syed V. Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells. Oncogene 2003, 22:4243-4256.
27. Hudelist G., Wuelfing P., Czerwenka K., Knofler M., Haider S., Fink-Retter A., Gschwantler-Kaulich D., Pfeiler G., Kubista E., Singer C.F. Beta-hCG/LH receptor (b-HCG/LH-R) expression is increased in invasive versus preinvasive breast cancer: implications for breast carcinogenesis?. J. Cancer Res. Clin. Oncol. 2009, 135:191-195.
28. Huhtaniemi I., White R., McArdle C.A., Persson B.E. Will GnRH antagonists improve prostate cancer treatment?. Trends Endocrinol. Metab. 2009, 20:43-50.
29. Huhtaniemi I.T., Dahl K.D., Rannikko S., Hsueh A.J. Serum bioactive and immunoreactive follicle-stimulating hormone in prostatic cancer patients during gonadotropin-releasing hormone agonist treatment and after orchidectomy. J. Clin. Endocrinol. Metab. 1988, 66:308-313.
30. Jankowska A., Gunderson S.I., Andrusiewicz M., Burczynska B., Szczerba A., Jarmolowski A., Nowak-Markwitz E., Warchol J.B. Reduction of human chorionic gonadotropin beta subunit expression by modified U1 snRNA caused apoptosis in cervical cancer cells. Mol. Cancer 2008, 7:26.
31. Ji Q., Chen P., Aoyoma C., Liu P. Increased expression of human luteinizing hormone/human chorionic gonadotropin receptor mRNA in human endometrial cancer. Mol. Cell. Probes 2002, 16:269-275.
32. Ji Q., Liu P.I., Chen P.K., Aoyama C. Follicle stimulating hormone-induced growth promotion and gene expression profiles on ovarian surface epithelial cells. Int. J. Cancer 2004, 112:803-814.
33. Jiang X., Russo I.H., Russo J. Alternately spliced luteinizing hormone/human chorionic gonadotropin receptor mRNA in human breast epithelial cells. Int. J. Oncol. 2002, 20:735-738.
34. Kammerman S., Demopoulos R.I., Raphael C., Ross J. Gonadotropic hormone binding to human ovarian tumors. Hum. Pathol. 1981, 12:886-890.
35. Kero J., Poutanen M., Zhang F.P., Rahman N., McNicol A.M., Nilson J.H., Keri R.A., Huhtaniemi I.T. Elevated luteinizing hormone induces expression of its receptor and promotes steroidogenesis in the adrenal cortex. J. Clin. Invest. 2000, 105:633-641.
36. Kobayashi F., Monma C., Nanbu K., Konishi I., Sagawa N., Mori T. Rapid growth of an ovarian clear cell carcinoma expressing LH/hCG receptor arising from endometriosis during early pregnancy. Gynecol. Oncol. 1996, 62:309-313.
37. Konishi I. Gonadotropins and ovarian carcinogenesis: a new era of basic research and its clinical implications. Int. J. Gynecol. Cancer 2006, 16:16-22.
38. Konishi I., Koshiyama M., Mandai M., Kuroda H., Yamamoto S., Nanbu K., Komatsu T., Matsushita K., Rao C.V., Mori T. Increased expression of LH/hCG receptors in endometrial hyperplasia and carcinoma in anovulatory women. Gynecol. Oncol. 1997, 65:273-280.
39. Kuijper T.M., Ruigrok-Ritstier K., Verhoef-Post M., Piersma D., Bruysters M.W., Berns E.M., Themmen A.P. LH receptor gene expression is essentially absent in breast tumor tissue: implications for treatment. Mol. Cell. Endocrinol. 2009, 302:58-64.
40. Kuroda H., Mandai M., Konishi I., Yura Y., Tsuruta Y., Hamid A.A., Nanbu K., Matsushita K., Mori T. Human chorionic gonadotropin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: possible role of up-regulation of insulin-like growth factor-1 by hCG. Int. J. Cancer 1998, 76:571-578.
41. Lacroix A., Hamet P., Boutin J.M. Leuprolide acetate therapy in luteinizing hormone-dependent Cushing's syndrome. N. Engl. J. Med. 1999, 341:1577-1581.
42. Lin J., Lei Z.M., Lojun S., Rao C.V., Satyaswaroop P.G., Day T.G. Increased expression of luteinizing hormone/human chorionic gonadotropin receptor gene in human endometrial carcinomas. J. Clin. Endocrinol. Metab. 1994, 79:1483-1491.
43. Lojun S., Bao S., Lei Z.M., Rao C.V. Presence of functional luteinizing hormone/chorionic gonadotropin (hCG) receptors in human breast cell lines: implications supporting the premise that hCG protects women against breast cancer. Biol. Reprod. 1997, 57:1202-1210.
44. Longo D.L., Young R.C. The natural history and treatment of ovarian cancer. Annu. Rev. Med. 1981, 32:475-490.
45. Lu J.J., Zheng Y., Kang X., Yuan J.M., Lauchlan S.C., Pike M.C., Zheng W. Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer. Gynecol. Oncol. 2000, 79:158-168.
46. Mandai M., Konishi I., Kuroda H., Fujii S. LH/hCG action and development of ovarian cancer-a short review on biological and clinical/epidemiological aspects. Mol. Cell. Endocrinol. 2007, 269:61-64.
47. Mandai M., Konishi I., Kuroda H., Fukumoto M., Komatsu T., Yamamoto S., Nanbu K., Rao C.V., Mori T. Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas. Eur. J. Cancer 1997, 33:1501-1507.
48. Mann R.J., Keri R.A., Nilson J.H. Consequences of elevated luteinizing hormone on diverse physiological systems: use of the LHbetaCTP transgenic mouse as a model of ovarian hyperstimulation-induced pathophysiology. Recent Prog. Horm. Res. 2003, 58:343-375.
49. Mariani S., Salvatori L., Basciani S., Arizzi M., Franco G., Petrangeli E., Spera G., Gnessi L. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer. J. Urol. 2006, 175:2072-2077. (discussion 2077).
50. Martikainen H., Penttinen J., Huhtaniemi I., Kauppila A. Gonadotropin-releasing hormone agonist analog therapy effective in ovarian granulosa cell malignancy. Gynecol. Oncol. 1989, 35:406-408.
51. Matzuk M.M., Kumar T.R., Shou W., Coerver K.A., Lau A.L., Behringer R.R., Finegold M.J. Transgenic models to study the roles of inhibins and activins in reproduction, oncogenesis, and development. Recent Prog. Horm. Res. 1996, 51:123-154. (discussion 155-7).
52. Maxwell G.L., Soisson A.P., Miles P. Failure of gonadotropin releasing hormone therapy in patients with metastatic ovarian sex cord stromal tumors. Oncology 1994, 51:356-359.
53. McSorley M.A., Alberg A.J., Allen D.S., Allen N.E., Brinton L.A., Dorgan J.F., Kaaks R., Rinaldi S., Helzlsouer K.J. Prediagnostic circulating follicle stimulating hormone concentrations and ovarian cancer risk. Int. J. Cancer 2009, 125:674-679.
54. Meduri G., Charnaux N., Loosfelt H., Jolivet A., Spyratos F., Brailly S., Milgrom E. Luteinizing hormone/human chorionic gonadotropin receptors in breast cancer. Cancer Res. 1997, 57:857-864.
55. Meduri G., Charnaux N., Spyratos F., Hacene K., Loosfelt H., Milgrom E. Luteinizing hormone receptor status and clinical, pathologic, and prognostic features in patients with breast carcinomas. Cancer 2003, 97:1810-1816.
56. Minegishi T., Kameda T., Hirakawa T., Abe K., Tano M., Ibuki Y. Expression of gonadotropin and activin receptor messenger ribonucleic acid in human ovarian epithelial neoplasms. Clin. Cancer Res. 2000, 6:2764-2770.
57. Noci I., Pillozzi S., Lastraioli E., Dabizzi S., Giachi M., Borrani E., Wimalasena J., Taddei G.L., Scarselli G., Arcangeli A. hLH/hCG-receptor expression correlates with in vitro invasiveness in human primary endometrial cancer. Gynecol. Oncol. 2008, 111:496-501.
58. Ohtani K., Sakamoto H., Kikuchi A., Nakayama Y., Idei T., Igarashi N., Matukawa T., Satoh K. Follicle-stimulating hormone promotes the growth of human epithelial ovarian cancer cells through the protein kinase C-mediated system. Cancer Lett. 2001, 166:207-213.
59. Osterholzer H.O., Johnson J.H., Nicosia S.V. An autoradiographic study of rabbit ovarian surface epithelium before and after ovulation. Biol. Reprod. 1985, 33:729-738.
60. Parrott J.A., Doraiswamy V., Kim G., Mosher R., Skinner M.K. Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol. Cell. Endocrinol. 2001, 172:213-222.
61. Paskeviciute L., Roed H., Engelholm S. No rules without exception: long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer. Gynecol. Oncol. 2002, 86:297-301.
62. Rahman N.A., Kananen Rilianawati K., Paukku T., Mikola M., Markkula M., Hamalainen T., Huhtaniemi I.T. Transgenic mouse models for gonadal tumorigenesis. Mol. Cell. Endocrinol. 1998, 145:167-174.
63. Rajaniemi H., Kauppila A., Ronnberg L., Selander K., Pystynen P. LH(hCG) receptor in benign and malignant tumors of human ovary. Acta Obstet. Gynecol. Scand. Suppl. 1981, 101:83-86.
64. Rimon E., Sasson R., Dantes A., Land-Bracha A., Amsterdam A. Gonadotropin-induced gene regulation in human granulosa cells obtained from IVF patients: modulation of genes coding for growth factors and their receptors and genes involved in cancer and other diseases. Int. J. Oncol. 2004, 24:1325-1338.
65. Rulli S.B., Kuorelahti A., Karaer O., Pelliniemi L.J., Poutanen M., Huhtaniemi I. Reproductive disturbances, pituitary lactotrope adenomas, and mammary gland tumors in transgenic female mice producing high levels of human chorionic gonadotropin. Endocrinology 2002, 143:4084-4095.
66. Saner-Amigh K., Mayhew B.A., Mantero F., Schiavi F., White P.C., Rao C.V., Rainey W.E. Elevated expression of luteinizing hormone receptor in aldosterone-producing adenomas. J. Clin. Endocrinol. Metab. 2006, 91:1136-1142.
67. Schildkraut J.M., Schwingl P.J., Bastos E., Evanoff A., Hughes C. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet. Gynecol. 1996, 88:554-559.
68. Srivastava P., Russo J., Mgbonyebi O.P., Russo I.H. Growth inhibition and activation of apoptotic gene expression by human chorionic gonadotropin in human breast epithelial cells. Anticancer Res. 1998, 18:4003-4010.
69. Stewart S.L., Querec T.D., Gruver B.N., O'Hare B., Babb J.S., Patriotis C. Gonadotropin and steroid hormones stimulate proliferation of the rat ovarian surface epithelium. J. Cell. Physiol. 2004, 198:119-124.
70. Stouffer R.L., Grodin M.S., Davis J.R., Surwit E.A. Investigation of binding sites for follicle-stimulating hormone and chorionic gonadotropin in human ovarian cancers. J. Clin. Endocrinol. Metab. 1984, 59:441-446.
71. Tao Y.X., Bao S., Ackermann D.M., Lei Z.M., Rao C.V. Expression of luteinizing hormone/human chorionic gonadotropin receptor gene in benign prostatic hyperplasia and in prostate carcinoma in humans. Biol. Reprod. 1997, 56:67-72.
72. Tao Y.X., Lei Z.M., Rao C.V. The presence of luteinizing hormone/human chorionic gonadotropin receptors in lactating rat mammary glands. Life Sci. 1997, 60:1297-1303.
73. Wang J., Luo F., Lu J.J., Chen P.K., Liu P., Zheng W. VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. Int. J. Cancer 2002, 97:163-167.
74. Whittemore A.S., Harris R., Itnyre J., Halpern J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. I. Methods. Collaborative Ovarian Cancer Group. Am. J. Epidemiol. 1992, 136:1175-1183.
75. Yan W., Burns K.H., Matzuk M.M. Genetic engineering to study testicular tumorigenesis. Apmis 2003, 111:174-181. (discussion 182-3).
76. Zheng W., Lu J.J., Luo F., Zheng Y., Feng Y., Felix J.C., Lauchlan S.C., Pike M.C. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol. Oncol. 2000, 76:80-88.
77. Zhou H., Luo M.P., Schonthal A.H., Pike M.C., Stallcup M.R., Blumenthal M., Zheng W., Dubeau L. Effect of reproductive hormones on ovarian epithelial tumors: I. Effect on cell cycle activity. Cancer Biol. Ther. 2002, 1:300-306.
78. Zwermann O., Suttmann Y., Bidlingmaier M., Beuschlein F., Reincke M. Screening for membrane hormone receptor expression in primary aldosteronism. Eur. J. Endocrinol. 2009, 160:443-451.
79. Zygmunt M., Herr F., Keller-Schoenwetter S., Kunzi-Rapp K., Munstedt K., Rao C.V., Lang U., Preissner K.T. Characterization of human chorionic gonadotropin as a novel angiogenic factor. J. Clin. Endocrinol. Metab. 2002, 87:5290-5296.